Trial Watch No. 21; November Edition 21
    Latest Newsletter
    November 16, 2026
    15 trials

    Trial Watch No. 21; November Edition 21

    The November 1–15, 2026 edition profiles 15 interventional clinical studies with registered start dates inside the first half of November. Four oncology studies sit alongside investigations of neurology and devices, obesity and diabetes, immune-mediated conditions, infections, Pompe disease, and engineered cell or gene therapies. Three are recorded as actual starts; twelve remain estimates.

    Get Trial Watch in your inbox

    Bi-weekly clinical trial intelligence; no spam, unsubscribe anytime.

    Trial Watch No. 20; October Edition 20
    Previous Edition
    October 31, 2026
    15 trials

    Trial Watch No. 20; October Edition 20

    The October 16–31, 2026 edition profiles 15 high-signal trials across oncology, neurology, cardiometabolic disease, immunology, respiratory disease, infectious disease, and rare and advanced modalities. Ten are Phase 3, including Novo Nordisk's 8,500-participant AMBIENCE cardiovascular outcomes trial, Merck's bladder-sparing TroFuse-055, and SWOG's ctDNA-guided MONITOR; the set runs down to a 10-participant base-editing study in WHIM syndrome.

    Trial Watch No. 19; October Edition 19
    Previous Edition
    October 15, 2026
    15 trials

    Trial Watch No. 19; October Edition 19

    The October 1–15, 2026 edition profiles 15 high-signal trials across oncology, transplant, cardiometabolic disease, immunology, respiratory disease, neurology, and advanced modalities. Tegoprubart enters Phase 3 in de novo kidney transplantation, AAV gene therapy enters Type 1 diabetes, and osteosarcoma moves into a large international platform study.

    Trial Watch No. 18; September Edition 18
    Previous Edition
    September 30, 2026
    15 trials

    Trial Watch No. 18; September Edition 18

    The September 16–30, 2026 edition profiles 15 high-signal trials across oncology, cardiometabolic disease, immunology, respiratory disease, and neurology. Two petrelintide Phase 3 studies total 6,400 participants; three ADC pivotals and a PD-1/VEGF bispecific advance alongside adjuvant KRAS G12C inhibition and dual-target autoimmune CAR-T.

    Trial Watch No. 17; September Edition 17
    Previous Edition
    September 15, 2026
    15 trials

    Trial Watch No. 17; September Edition 17

    Early-September 2026 clinical intelligence (September 1 to September 15). 15 high-signal trials across oncology, vaccines, cardiometabolic, immunology, respiratory and advanced modalities; featuring GSK's 54,000-patient mRNA seasonal influenza vaccine Phase 3 in adults 65+, the largest mRNA-vaccine efficacy trial ever registered; Eli Lilly extending the metabolic franchise across three new age brackets with orforglipron in overweight adults, orforglipron in pediatric T2D and tirzepatide in pediatric obesity age 6 to 12; Hengrui's trastuzumab rezetecan plus adebrelimab in residual TNBC; the TiTan dual-bispecific Phase 3 in MRD-positive myeloma; Incyte's INCA033989, the first Phase 3 of a mutant-CALR-targeted therapy; argenx's adimanebart, the first pivotal in congenital myasthenic syndrome; CRISPR Therapeutics' CTX112 allogeneic CD19 CAR-T in neurologic autoimmune disease; and Prime Medicine's PM577a, the first clinical Prime Editing trial in any indication.

    Trial Watch No. 16; August Edition 16
    Previous Edition
    August 31, 2026
    15 trials

    Trial Watch No. 16; August Edition 16

    Late-August 2026 clinical intelligence (August 16 to August 31). 15 high-signal trials across oncology, cardiometabolic, immunology, respiratory and advanced modalities; featuring AstraZeneca's most concentrated Phase 3 push in modern pharma with Elevate-CKD (7,000 pts), Elevate-HF (6,950 pts), SELENE 1 (2,500 pts) and the DURGA-6 dual BCMA/CD19 CAR-T tested head-to-head against autologous stem cell transplant; Myeloid Therapeutics' CRT-402, the first in vivo CD19 CAR-T in refractory lupus, scleroderma and myositis; Amgen's DeLLphi-315 subcutaneous tarlatamab conversion in ES-SCLC; Pfizer's Tilrekimig monotherapy head-to-head against Dupixent; GSK's six-trial PERSIST felcorekibart respiratory program; Regeneron's ROXI-PEAK extending the Factor XI franchise past 26,000 patients; and the first pivotal to define a standard of care in Richter transformation.

    Trial Watch No. 15; August Edition 15
    Previous Edition
    August 15, 2026
    15 trials

    Trial Watch No. 15; August Edition 15

    Early-August 2026 clinical intelligence (August 1 to August 15). 15 high-signal trials across oncology, cardiometabolic, immunology, neurology and advanced modalities; featuring CRISPR Therapeutics' CTX340, the first in vivo LNP-CRISPR editing of the angiotensinogen gene for essential hypertension; Nektar's Rezpegaldesleukin and Pfizer's Tilrekimig opening Phase 3 in atopic dermatitis in the same window; Exelixis's ctDNA-defined adjuvant CRC Phase 3; UBT251 UNIGUIDE-1 in treatment-naive Type 2 diabetes; AbbVie's ABBV-295 amylin analog; the 800-patient MAVRIC metformin trial in IPF; GSK's momelotinib, the first pivotal in VEXAS syndrome; Otsuka's ulotaront in generalized anxiety disorder; and the VA's psilocybin Phase 3, the first federal-scale psychedelic pivotal.

    Trial Watch No. 14; July Edition 14
    Previous Edition
    July 31, 2026
    15 trials

    Trial Watch No. 14; July Edition 14

    Late-July 2026 clinical intelligence (July 16 to July 31). 15 high-signal trials across oncology, cardiometabolic, immunology, neurology and advanced modalities; featuring Regeneron's ROXI-EVEREST, the largest atrial fibrillation Phase 3 ever registered at 15,364 patients; GSK's NEBULA-1 Efimosfermin Alfa in MASH F4 compensated cirrhosis; Amgen's 3,200-patient MariTide long-term extension; UBT251 head-to-head against semaglutide; Regeneron's Olatorepatide obesity entry; AstraZeneca's adjuvant Dato-DXd plus rilvegostomig in high-risk MIBC; AbbVie's 2,000-patient IBD platform basket; UCL's SMART Alzheimer's platform; and CSL Behring's IgPro20, the first Phase 3 in post-CAR-T secondary immunodeficiency.

    Trial Watch No. 13; July Edition 13
    Previous Edition
    July 15, 2026
    15 trials

    Trial Watch No. 13; July Edition 13

    Early-July 2026 clinical intelligence (July 1 to July 15). 15 high-signal trials across oncology, cardiometabolic, immunology, neurology and advanced modalities; featuring AstraZeneca's AZD4045 allogeneic BCMA CAR T, Fate Therapeutics' FT819 iPSC CAR T in refractory SLE with lupus nephritis, and BrainChild Bio's BCB-276 locoregional B7-H3 CAR T in diffuse intrinsic pontine glioma; Genfleet's GFH375, the first Phase 3 of any KRAS G12D inhibitor; Structure Therapeutics' 3,600-patient ACCOMPLISH-2 oral GLP-1 obesity program and AstraZeneca's Eluminate-1 elecoglipron; plus Leeds's 1,226-patient iFIT quintuplet and PrECOG's Belantamab Mafodotin head-to-head against daratumumab in newly diagnosed Multiple Myeloma.

    Trial Watch No. 12; June Edition 12
    Previous Edition
    June 30, 2026
    15 trials

    Trial Watch No. 12; June Edition 12

    Late-June 2026 clinical intelligence (June 16 to June 30). 15 high-signal trials across oncology, cardiometabolic, neurology and advanced modalities; featuring Regeneron's ROXI-CAT-II FXI antibody in cancer-associated VTE, Heidelberg's Teclistamab quintuplet in 1L newly diagnosed transplant-eligible MM, WSG's Sacituzumab + Pembrolizumab neoadjuvant TNBC program, Merck's KANDLELIT-015 MK-1084 in KRAS G12C+ Stage III NSCLC, Roche-Carmot's Petrelintide + Enicepatide combo and Boehringer's BI 3034701 obesity Phase 2b, plus T-MAXIMUM's MT027 intracerebroventricular universal CAR T in recurrent GBM.

    Trial Watch No. 11; June Edition 11
    Previous Edition
    June 15, 2026
    15 trials

    Trial Watch No. 11; June Edition 11

    Early-June 2026 clinical intelligence (June 1 to June 15). 15 high-signal trials across oncology, cardiometabolic, immunology, neurology and advanced modalities; featuring GSK's Velzatinib challenging imatinib head-to-head in 1L GIST, Nurix's NX-5948 as the first BTK degrader in Phase 3, Regeneron's 1,570-patient Linvoseltamab MM program, APHP's 4,336-patient Low-EPI OHCA epinephrine trial, and Affinia's UPBEAT AFTX-201; the first AAV gene therapy for a hereditary cardiomyopathy.

    Trial Watch Newsletter; May Edition 10
    Previous Edition
    May 31, 2026
    16 trials

    Trial Watch Newsletter; May Edition 10

    Late-May 2026 clinical intelligence (May 16 to May 31). 16 high-signal trials across oncology, cardiometabolic, immunology, neurology and advanced modalities; featuring Novo Nordisk's CagriSema and AMAZE 8 head-to-heads against semaglutide, Janssen's JNJ-78934804 vs Guselkumab in parallel Crohn's and UC programs, Regeneron's 7,050-patient ROXI-PALISADE FXI program, Molecular Partners' DLL3 alpha-emitter, and AbbVie's NAAVIGATE AAV gene therapy in diabetic retinopathy.

    Trial Watch Newsletter; May Edition 9
    Previous Edition
    May 15, 2026
    15 trials

    Trial Watch Newsletter; May Edition 9

    Early-May 2026 clinical intelligence (May 1 to May 15). 15 high-signal trials across oncology, cardiometabolic, immunology and neurology; featuring Merck's Intismeran mRNA vaccine in resected NSCLC, parallel ADC Phase 3 programs from AbbVie and EMD Serono in refractory mCRC, Novartis DLL3 CAR-T in SCLC, and the Pelacarsen Lp(a)HORIZON extension at 5,700 patients across 492 sites.

    Trial Watch Newsletter; April Edition 8
    Previous Edition
    April 30, 2026
    15 trials

    Trial Watch Newsletter; April Edition 8

    Late-April 2026 clinical intelligence (Apr 16 to Apr 30). 15 high-signal trials across oncology, cardiometabolic & cardiopulmonary, immunology, advanced modalities and infectious disease; featuring BMS CD19 CAR-T in systemic sclerosis, Roche NXT007 vs Hemlibra, Janssen IL-23 head-to-head in Crohn's, and HELP iPSC-cardiomyocytes in heart failure.

    Trial Watch Newsletter; April Edition 7
    Previous Edition
    April 14, 2026
    9 trials

    Trial Watch Newsletter; April Edition 7

    Early-April 2026 U.S. clinical-trial announcements (Apr 1 to 14). 9 trials across cardiometabolic, oncology, infectious disease, and rare disease; featuring gene therapy for heart failure, pediatric CAR T, Marburg vaccine, and oral rare disease therapies.

    Trial Watch Newsletter; March Edition 6
    Previous Edition
    March 31, 2026
    9 trials

    Trial Watch Newsletter; March Edition 6

    Late-March 2026 U.S. clinical-trial announcements (Mar 14–31). 9 trials across precision oncology, rare disease, pulmonary disease, cardiometabolic, and sleep medicine; featuring targeted protein degradation, inhaled reformulations, and pivotal Phase 3 programs.

    Trial Watch Newsletter; Mar 2026 Edition 5
    Previous Edition
    March 15, 2026
    15 trials

    Trial Watch Newsletter; Mar 2026 Edition 5

    Early-March 2026 U.S. clinical-trial announcements (Mar 1–15). Phase 2–3 trials across oncology, neurology, rare & pulmonary diseases, infectious disease, and advanced gene-editing modalities; featuring 15 trials including CRISPR therapies, protein degraders, and novel anti-infectives.

    Trial Watch Newsletter; Feb 2026 Edition 4
    Previous Edition
    February 28, 2026
    11 trials

    Trial Watch Newsletter; Feb 2026 Edition 4

    Late-February 2026 U.S. clinical-trial activity (Feb 13–28). Oncology, neurology, infectious disease, rare disorders, and advanced genetic therapies; featuring 11 trials across precision oncology, gene editing, preventive immunology, and innovative trial designs.

    Trial Watch Newsletter; Feb 2026 Edition 3
    Previous Edition
    February 15, 2026
    8 trials

    Trial Watch Newsletter; Feb 2026 Edition 3

    Early-February 2026 U.S. clinical-trial activity (Feb 1–15). Phase 1–4 trials in breast cancer, prostate cancer, Alzheimer's disease, Parkinson's disease and colon cancer, with a focus on Phase 2 innovations.

    Trial Watch Newsletter; January Edition 2
    Previous Edition
    January 30, 2026
    5 trials

    Trial Watch Newsletter; January Edition 2

    Early-phase clinical trial intelligence from the U.S. highlighting newly announced Phase 1 and Phase 2 trials across oncology and neurodegenerative diseases.

    Trial Watch Newsletter; January Edition 1
    Previous Edition
    January 15, 2026
    11 trials

    Trial Watch Newsletter; January Edition 1

    A snapshot of newly announced and progressing early-phase clinical trials across oncology and neurodegenerative disease, with a focus on U.S. activity.

    Latest Trial Updates

    Trial Watch Articles

    In-depth coverage of clinical trial trends, breakthroughs, and regulatory updates shaping the industry

    Parkinson's Disease; RNDP-001 (iPSC-Derived Dopaminergic Neurons); Phase 1 Started
    TrendingCell Therapy

    Parkinson's Disease; RNDP-001 (iPSC-Derived Dopaminergic Neurons); Phase 1 Started

    Kenai Therapeutics doses first patient in Phase 1 REPLACE trial evaluating allogeneic iPSC-derived dopaminergic neuron therapy for moderate to moderate-severe Parkinson's disease.

    December 15, 2025
    6 min read
    Alzheimer's Disease; Intranasal Foralumab (Anti-CD3 mAb); Phase 2 Started
    Neurology

    Alzheimer's Disease; Intranasal Foralumab (Anti-CD3 mAb); Phase 2 Started

    Tiziana Life Sciences reports first patient dosing in Phase 2 trial of intranasal foralumab for early Alzheimer's, evaluating monotherapy and combination with anti-amyloid antibodies.

    December 17, 2025
    5 min read
    Breast Cancer (Brain Metastases); Utidelone + Capecitabine; Pivotal Trial Started
    Oncology

    Breast Cancer (Brain Metastases); Utidelone + Capecitabine; Pivotal Trial Started

    Biostar Pharma doses first patient in U.S. pivotal trial of utidelone plus capecitabine for HER2-negative breast cancer with brain metastases across 20 leading cancer centers.

    December 15, 2025
    5 min read
    Trial Landscape: Neurodegenerative & Cancer Trends
    Industry Trends

    Trial Landscape: Neurodegenerative & Cancer Trends

    Weekly analysis reveals ongoing momentum in major trials despite light launch week, highlighting diversifying therapeutic modalities and hybrid trial models.

    December 1, 2025
    7 min read
    Prostate Cancer; AB001 (PSMA-targeted Alpha Radioligand Therapy); Phase 1 Started
    Oncology

    Prostate Cancer; AB001 (PSMA-targeted Alpha Radioligand Therapy); Phase 1 Started

    ARTBIO doses first patient in Phase 1 trial for metastatic castration-resistant prostate cancer using Lead-212 alpha radioligand therapy targeting PSMA.

    November 25, 2025
    8 min read
    Parkinson's Disease; VT-5006 (Gut-Selective Small Molecule); Phase 1 Launched
    Neurology

    Parkinson's Disease; VT-5006 (Gut-Selective Small Molecule); Phase 1 Launched

    Vertero Therapeutics launches first-in-class gut-targeted therapy aiming for disease-modification through the gut-brain axis in Parkinson's patients.

    November 24, 2025
    9 min read
    Orelabrutinib (BTK Inhibitor) for Multiple Sclerosis; New Rights Deal & Expected Trial Push
    Neurology

    Orelabrutinib (BTK Inhibitor) for Multiple Sclerosis; New Rights Deal & Expected Trial Push

    Zenas Biopharma acquires global rights to develop Orelabrutinib for MS, signaling potential Phase 2/3 trials and pipeline renewal in neuro-immunology.

    October 2025
    6 min read
    TRX319; First Allogeneic CAR-Engineered Regulatory T-cell Therapy Cleared for Progressive MS
    Cell Therapy

    TRX319; First Allogeneic CAR-Engineered Regulatory T-cell Therapy Cleared for Progressive MS

    FDA clears IND for TRX319, pioneering CAR-engineered Treg cell therapy for progressive MS, representing a paradigm shift in neuro-autoimmune treatment.

    October 15, 2025
    7 min read
    Interstitial Lung Disease / Pulmonary Fibrosis; Expanded Trial Landscape
    Pulmonology

    Interstitial Lung Disease / Pulmonary Fibrosis; Expanded Trial Landscape

    October 2025 sees increased trial activity across ILD and pulmonary fibrosis, including novel antifibrotic therapies and biomarker-driven investigations.

    October 2025
    6 min read